Ken Griffin Aquestive Therapeutics, Inc. Transaction History

Citadel Advisors LLC

$483 Billion
Q2 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Aquestive Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 61,400 shares of AQST stock, worth $288,580. This represents 0.0% of its overall portfolio holdings.

Number of Shares

61,400

Previous 33,500 83.28%

Holding current value

$288,580

Previous $142,000 11.97%

% of portfolio

0.0%

Previous 0.0%

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$2.31 - $4.5 $130,422 - $254,070	-56,460 Reduced 25.17%	167,813 $436,000
Q1 2024 May 15, 2024	BUY	$2.01 - $6.09 $113,476 - $343,817	56,456 Added 33.64%	224,273 $955,000
Q4 2023 Feb 14, 2024	BUY	$1.29 - $2.47 $212,994 - $407,826	165,112 Added 6103.96%	167,817 $338,000
Q3 2023 Nov 14, 2023	SELL	$1.5 - $2.24 $873 - $1,303	-582 Reduced 17.71%	2,705 $4,000
Q2 2023 Aug 14, 2023	BUY	$1.06 - $2.49 $3,484 - $8,184	3,287 New	3,287 $5,000
Q4 2022 Feb 14, 2023	SELL	$0.77 - $1.18 $11,667 - $17,880	-15,153 Reduced 83.89%	2,910 $2,000
Q3 2022 Nov 14, 2022	SELL	$0.63 - $1.73 $33,977 - $93,302	-53,932 Reduced 74.91%	18,063 $21,000
Q2 2022 Aug 15, 2022	BUY	$0.64 - $2.57 $22,531 - $90,476	35,205 Added 95.69%	71,995 $46,000
Q1 2022 May 16, 2022	SELL	$2.28 - $4.26 $139,257 - $260,192	-61,078 Reduced 62.41%	36,790 $96,000
Q4 2021 Feb 14, 2022	BUY	$3.69 - $6.37 $207,219 - $357,720	56,157 Added 134.63%	97,868 $380,000
Q3 2021 Nov 15, 2021	SELL	$3.25 - $4.66 $109,694 - $157,284	-33,752 Reduced 44.73%	41,711 $182,000
Q1 2021 May 17, 2021	BUY	$4.17 - $6.73 $213,541 - $344,636	51,209 Added 211.14%	75,463 $392,000
Q4 2020 Feb 16, 2021	SELL	$4.65 - $7.79 $147,581 - $247,239	-31,738 Reduced 56.68%	24,254 $130,000
Q3 2020 Nov 16, 2020	BUY	$4.12 - $9.09 $122,631 - $270,563	29,765 Added 113.49%	55,992 $272,000
Q2 2020 Aug 14, 2020	BUY	$1.84 - $6.44 $28,713 - $100,496	15,605 Added 146.91%	26,227 $127,000
Q1 2020 May 15, 2020	SELL	$1.54 - $6.75 $23,343 - $102,316	-15,158 Reduced 58.8%	10,622 $23,000
Q3 2018 Nov 13, 2018	BUY	$15.0 - $18.96 $386,700 - $488,788	25,780 New	25,780 $0

Others Institutions Holding AQST

# of Institutions

Shares Held

42.7M

Call Options Held

271K

Put Options Held

212K

View Full List

About Aquestive Therapeutics, Inc.

Ticker AQST
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,350,700
Market Cap $251M
Description
Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual f...

More about AQST

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account